TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03281954

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Following randomization, patients will receive Paclitaxel 80 mg/m2 IV weekly x 12 doses + Carboplatin AUC of 5 IV Day 1 every 3 weeks for 4 cycles + placebo IV Day 1 every 3 weeks for 4 doses.~Followed 2-3 weeks later by Doxorubicin (A) 60 mg/m2 IV + cyclophosphamide (C) 600 mg/m2 IV Day 1 every 2 or 3 weeks for 4 cycles OR Epirubicin (E) 90 mg/m2 IV + cyclophosphamide (C) 600 mg/m2 IV Day 1 every 2 or 3 weeks for 4 cycles.~+ placebo IV Day 1 every 3 weeks for 3 to 4 doses depending on AC/EC schedule used.~Approximately 3-4 weeks later: Surgery (Lumpectomy or mastectomy and axillary staging), followed by placebo IV Day 1 every 3 weeks after surgery until 1 year after the first dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Following randomization, patients will receive Paclitaxel 80 mg/m2 IV weekly x 12 doses + Carboplatin AUC of 5 IV Day 1 every 3 weeks for 4 cycles + Atezolizumab 1200 mg Day 1 every 3 weeks for 4 doses.~Followed 2-3 weeks later by Doxorubicin (A) 60 mg/m2 IV + cyclophosphamide (C) 600 mg/m2 IV Day 1 every 2 or 3 weeks for 4 cycles OR Epirubicin (E) 90 mg/m2 IV + cyclophosphamide (C) 600 mg/m2 IV Day 1 every 2 or 3 weeks for 4 cycles.~+ Atezolizumab 1200 mg Day 1 every 3 weeks for 3 to 4 doses depending on AC/EC schedule used.~Approximately 3-4 weeks later: Surgery (Lumpectomy or mastectomy and axillary staging), followed by Atezolizumab 1200 mg Day 1 every 3 weeks after surgery until 1 year after the first dose.
Study: NCT02310685

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comprehensive e-health wellness program
Description: Participants randomized to this arm will have complete access to the myhealthcheckup website equipped with online tools including health assessments with coaching modules, educational material with quizzes, exercise challenges and motivational tips. The subject will meet with the pharmacist on 4 occasions (initial, 3, 6, 12 months) to update the cardiovascular risk profile, BP, weight, waist circumference and lipid profile. All interventions that were prespecified to be administered as part of the protocol, even if a particular intervention is not of interest.
Study: NCT04295421

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: adductor canal block
Description: ACB was done in the immediate postoperative period under a high-frequency ultrasound guidance in which the adductor canal was identified beneath the sartorius muscle and 20 ml of 0.2% ropivacaine was injected in the canal using a 22-gauge 100-mm short-beveled regional block needle and a catheter was kept for 48H with 4 ml/h ropivacaine 0.2%.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adductor canal block
Description: ACB was done in the immediate postoperative period under a high-frequency ultrasound guidance in which the adductor canal was identified beneath the sartorius muscle and 20 ml of 0.2% ropivacaine was injected in the canal using a 22-gauge 100-mm short-beveled regional block needle and a catheter was kept for 48H with 4 ml/h ropivacaine 0.2%.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IPACK block
Description: IPACK block was realized after spinal anesthesia with 40 ml 0.2% ropivacaine and at the end of surgery , patients were given ACB with 20 ml 0.2% ropivacaine and continued with 4 ml/H saline for 48H
Study: NCT01299623

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparison of evidential versus non-evidential education on women's breast cancer prevention behaviors
Description: Participants will be randomized to either the evidential or non-evidential group. Both groups will receive primarily the same information, except one group will receive information that is more tailored to African American women, while participants in the other group will receive general information about breast cancer prevention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparison of evidential versus non-evidential education on women's breast cancer prevention behaviors
Description: Participants will be randomized to either the evidential or non-evidential group. Both groups will receive primarily the same information, except one group will receive information that is more tailored to African American women, while participants in the other group will receive general information about breast cancer prevention.
Study: NCT01459965

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ERCP with 10 French biliary plastic stent placement
Description: Stent placement of a 10 French biliary plastic stent

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ERCP with 11.5 French biliary plastic stent
Description: biliary plastic stent placement
Study: NCT01154309

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group CBT for Depression and AOD Disorders
Description: 18 sessions of 2-hour group CBT
Study: NCT03951740

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitbit Charge 2
Description: Energy expenditure (kcal) assessed by this activity tracker will be compared with indirect calorimetry (Oxycon Mobile) during a laboratory activity protocol. Two groups will be assessed: patients with stable coronary artery disease (CAD) and patients with heart failure with reduced ejection fraction (HFrEF).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mio Slice
Description: Energy expenditure (kcal) assessed by this activity tracker will be compared with indirect calorimetry (Oxycon Mobile) during a laboratory activity protocol. Two groups will be assessed: patients with stable coronary artery disease (CAD) and patients with heart failure with reduced ejection fraction (HFrEF).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oxycon Mobile
Description: The Oxycon Mobile will be used as the reference method/golden standard to calculate energy expenditure (kcal). This device (consisting of a face mask and gas analyzer unit) will be worn during the entire laboratory activity protocol.~Two groups will be assessed: patients with stable coronary artery disease (CAD) and patients with heart failure with reduced ejection fraction (HFrEF).
Study: NCT00380978

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: combined spinal epidural analgesia
Description: Analgesia was initiated in the early group using a standard needle-through-needle technique with intrathecal fentanyl 25 mcg and an epidural test dose of lidocaine 15 mg/ml and epinephrine 5 mcg/ml in 3ml. At the second analgesia request, the cervix was examined. Epidural analgesia was initiated with a dilute bupivicaine/fentanyl solution if the cervix was less than 4 cm. If the cervix was 4 cm or more, epidural analgesia was initiated with bupivicaine 1.25 mg/ml. If no cervical exam was performed at the second request for analgesia, the cervix was assumed to be at least 4 cm dilated. Thereafter, analgesia was maintained in all participants in the early group with patient-controlled epidural analgesia.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: late analgesia (systemic)
Description: Analgesia was initiated in the late group with hydromorphone 1mg intramuscularly (IM) and 1 mg intravenously (IV). If the cervix was less than 4 cm at the second analgesia request, hydromorphone analgesia was repeated. Epidural analgesia was initiated with bupivicaine 1.25 mg/ml if the cervix was 4 cm or more. At the third analgesia request, epidural analgesia was initiated regardless of cervical dilation. Thereafter, epidural analgesia was maintained with patient controlled analgesia until delivery.
Study: NCT03147365

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercises
Description: Aerobic exercises will do by using treadmill for children of study group A. it will consist of (max.incline15% - max. speed - heart rate grips and wireless chest strap - smooth virtual fitness trainer - smooth drop folding frame - impression shock absorption cushioning system).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified strength training
Description: Dumbbells will be used to conduct the modified strength training program for children of group B. This exercises included five exercises for the main muscle groups: bench press, leg press, seat row, leg extension and lat pull down.
Study: NCT00786487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20% lipid infusion
Description: 1.5 ml/min for 6 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20% lipid infusion
Description: 1.5 ml/min for 6 hours
Study: NCT03137849

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Yoga Poses
Description: Yoga poses routine including specific muscles contractions known as bandhas (pelvic floor, core and throat/neck contraction) within each pose, which are advised to be done with steadiness and comfort.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Breath Control
Description: Ujjayi pranayama (Victorious breath) Inhalation and exhalation are both done through the nose. The ocean sound is created by moving the glottis as air passes in and out. As the throat passage is narrowed so, too, is the airway, the passage of air through which creates a rushing sound. The length and speed of the breath is controlled by the diaphragm, the Strengthening of which is, in part, the purpose of ujjayi. The inhalations and exhalations are equal in duration.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Breath Control
Description: Ujjayi pranayama (Victorious breath) Inhalation and exhalation are both done through the nose. The ocean sound is created by moving the glottis as air passes in and out. As the throat passage is narrowed so, too, is the airway, the passage of air through which creates a rushing sound. The length and speed of the breath is controlled by the diaphragm, the Strengthening of which is, in part, the purpose of ujjayi. The inhalations and exhalations are equal in duration.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stretching exercises
Description: Stretching exercises routine based on dynamic and static exercises excluding those similar to yoga poses. This routine works on great range of motion of all body joints and main muscles groups/ chains.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stretching exercises
Description: Stretching exercises routine based on dynamic and static exercises excluding those similar to yoga poses. This routine works on great range of motion of all body joints and main muscles groups/ chains.
Study: NCT02535585

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: knotted anchors (SutureTak biocomposite 3.0 mm)
Description: Arthroscopic repair of the labral lesion with knotted anchors (SutureTak biocomposite 3.0 mm).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: knotless anchors (PushLock biocomposite 2.9 mm knotless)
Description: Arthroscopic repair of the labral lesion with knotless anchors (PushLock biocomposite 2.9 mm knotless)
Study: NCT01051648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intra ocular injection of triamcinolone acetonide
Description: In all patients triamcinolone acetonide was prepared by keeping the bottle vertical to allow sedimentation of crystals thus removing the vehicle. It was then injected into the anterior chamber (2 ml with concentration 20 mg/ml) just prior to anterior vitrectomy. The direction of the tip of the needle was kept away from the corneal endothelium to minimize endothelial toxicity. Triamcinolone was removed as quickly \& completely as possible after finishing anterior vitrectomy
Study: NCT03610984

Intervention type: OTHER
Intervention: type 1 diabetes structured education
Description: The structured education is based on a regular outpatients visit.It is an education that integrated several diabetes related subjects,which mainly aimed at T1D self-management.
Study: NCT03610685

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Given daily for 2 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Given daily for 2 weeks
Study: NCT04131855

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pumice prophylaxis
Description: Pumicing the teeth is the recommended prophylaxis to be used prior to the application of the self etch primer by the manufacturer - 3M Unitek Transbond Plus Self Etch Primer which will be used in the experiment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No pumice prophylaxis
Description: Pumice prophylaxis will not be used as per manufacturers instructions.
Study: NCT03340922

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automatic annotation of LAT (WF-method)
Description: Automatic annotation of LAT during PVC activation mapping. Acquisition of points will be automatically performed using the Wavefront (WF) annotation tool integrated into CARTO navigation system.
Study: NCT02039856

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: National policy guidance
Description: VA Handbooks on policy and practice for PACT implementation guidance and on delivery of comprehensive women's health services disseminated to all VA facilities
Study: NCT04374058

Intervention type: OTHER
Intervention: less-frequency hemodialysis
Description: Patients of treatment group would be evaluated quarterly

Intervention type: OTHER
Intervention: less-frequency hemodialysis
Description: Patients of treatment group would be evaluated quarterly
Study: NCT03340922

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manual annotation of LAT (M-method)
Description: Conventional, manual annotation of LAT during PVC activation mapping. Acquisition of points will be performed using the CARTO navigation system by an expert electrophysiologist.
Study: NCT02296307

Intervention type: OTHER
Intervention: Blood test: CA-125 biomarker
Description: * CA-125 biomarker blood test at visit 1, day 1.~* CA-125 biomarker blood test at visit 2, week 6.
Study: NCT02607228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alobresib
Description: Tablet administered orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alobresib
Description: Tablet administered orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alobresib
Description: Tablet administered orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alobresib
Description: Tablet administered orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alobresib
Description: Tablet administered orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Capsules administered orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Capsules administered orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Capsules administered orally once daily.
Study: NCT02348307

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FYU-981, (Oral single dosing)
Description: Subjects randomized to the FYU-981 arm receive active drug, FYU-981.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, (Oral single dosing)
Description: Subjects randomized to the placebo arm receive placebo.
Study: NCT02980627

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapy with Mobile App Enhancement
Description: Treatment includes 12 weekly therapy sessions with daily RR app use between sessions. Intervention is CBT-based and specifically draws from ACT. ACT is a contextual behavior therapy that emphasizes the function of behavior (e.g., affect regulation) and helps individuals accept (or tolerate) emotional discomfort for a broader purpose (i.e., personal values). Broadly, treatment will focus on improving diabetes management by increasing patients' capacity to effectively cope with psychological barriers to self-care using acceptance and mindfulness strategies.
Study: NCT00586976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: 0.3% ropivacaine infusion at 4 ml/hr for 64 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline infusion at 4 ml/hour for 64 hours.
Study: NCT01976143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-102
Study: NCT04194814

Intervention type: DRUG
Group type: OTHER
Intervention: crisaborole (2%) ointment
Description: twice daily application on one forearm for 4 weeks (randomised site allocation)

Intervention type: DRUG
Group type: OTHER
Intervention: betamethasone valerate 0.1% cream
Description: twice daily application on one forearm for 4 weeks (randomised site allocation)
Study: NCT01020253

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alendronate, alfacalcidol
Description: Alendronate: 5mg per day, Tablet, Duration is 48 weeks. Alfacalcidol: 1μg per day, Tablet, Duration is 48 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alendronate, alfacalcidol
Description: Alendronate: 5mg per day, Tablet, Duration is 48 weeks. Alfacalcidol: 1μg per day, Tablet, Duration is 48 weeks.

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: alendronate, alfacalcidol
Description: Alendronate: 5mg per day, Tablet, Duration is 48 weeks. Alfacalcidol: 1μg per day, Tablet, Duration is 48 weeks.
Study: NCT01092663

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colesevelam HCl
Description: Subjects will be given 3.75 g/day. Subjects will be given 3 tablets (625mg each) with breakfast and 3 tablets (625mg) with dinner for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colesevelam HCl
Description: Subjects will be given 3.75 g/day. Subjects will be given 3 tablets (625mg each) with breakfast and 3 tablets (625mg) with dinner for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Subjects will be given 100mg/day. Subjects will be given 1 tablet (100mg) with breakfast for 12 weeks.
Study: NCT03234491

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DiAS
Description: Diabetes Assistant (DiAS) hybrid closed loop system.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DiAS
Description: Diabetes Assistant (DiAS) hybrid closed loop system.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DiAS
Description: Diabetes Assistant (DiAS) hybrid closed loop system.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Afrezza low dose
Description: Afrezza inhaled insulin low dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Afrezza high dose
Description: Afrezza inhaled insulin high dose.
Study: NCT01821482

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic and Cytokine-induced Killer Cells
Study: NCT03678168

Intervention type: OTHER
Group type: OTHER
Intervention: Throat Pack
Description: Post rhinology surgery throat packs will be used as a control to compare against the intervention (Pharyngeal tampons)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharyngeal Tampons
Description: Post rhinology surgery Pharyngeal Tampons will be used as an intervention to compare against the throat pack (control)
Study: NCT01274429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peanut flour
Description: Peanut flour that is ingested daily and administered in gradually increasing amounts up to a maximum maintenance dose.
Study: NCT03565237

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RIXUBIS: On-Demand
Description: RIXUBIS used under standard clinical practice in India: On-Demand treatment.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RIXUBIS: Prophylaxis
Description: RIXUBIS used under standard clinical practice in India: Prophylaxis treatment.
Study: NCT04564872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK7653 10 mg Q2W
Description: HSK7653 5 mg (2 tablets) and placebo 25 mg (1 tablet) Q2W, placebo of linagliptin 5 mg QD, oral, week 1 to week 24; HSK7653 25 mg Q2W, oral, week 25 to week 52.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK7653 25 mg Q2W
Description: HSK7653 25 mg (1 tablet) and placebo 5 mg (2 tablets) Q2W, placebo of linagliptin 5 mg QD, oral, week 1 to week 24; HSK7653 25 mg (1 tablet) Q2W, oral, week 25 to week 52.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linagliptin 5 mg QD
Description: Linagliptin 5 mg QD, placebo of HSK7653 25 mg (1 tablet) and 5 mg (2 tablets) Q2W, oral, week 1 to week 24; HSK7653 25 mg Q2W, oral, week 25 to week 52.
Study: NCT04506333

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A&D UA-651 Blood Pressure Monitor
Description: Test device to be validated.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A&D UA-651 Blood Pressure Monitor
Description: Test device to be validated.
Study: NCT02296307

Intervention type: OTHER
Intervention: Second Test: Transvaginal Ultrasound
Description: -Transvaginal Ultrasound at visit 1, day 1.

Intervention type: OTHER
Intervention: Follow-up phone call
Description: Phone call 6 months after last visit to verify continued health.
Study: NCT00936819

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Plasma-Lyte A and 25% Autologous Plasma
Description: Single dose of 8 mls given by investigator via intracoronary injection into stent of infarct-related artery

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous EPCs
Description: Single dose of 20 million cells in 8 mls given by investigator via intracoronary injection into stent of infarct-related artery

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous EPCs Transfected with human eNOS
Description: Single dose of 20 million cells in 8 mls given by investigator via intracoronary injection into stent of infarct-related artery
Study: NCT01318356

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Description: CBT will consist of a protocolized intervention of 12 sessions during a period of 24 weeks. It starts with goal setting and psycho-education on the possible role of cognitions and behavior in maintaining the fatigue. The maintaining factors will subsequently be addressed (regulation of sleep-wake cycle, gradual increasing activity, reformulating fatigue related cognitions).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: Antibiotic therapy will consist of doxycycline once daily 200 mg (in 1 capsule) for 24 weeks. Patients will be monitored 4, 8, 16 and 26 weeks after start for side effects (rash, liver enzymes). Antibiotics will be stopped in case of side effects or pregnancy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in the placebo group will receive once daily 1 placebo capsule identical in appearance to the doxycycline for 24 weeks and have the same visits and monitoring for side effects as the patients randomized to doxycycline (Patients will be monitored 4, 8, 16 and 26 weeks)